drugset / Trial / NCT05507593
Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, phase I clinical trial aimed to evaluate the safety and efficacy of DLL3-CAR-NK cells treatment for relapsed and refractory extensive small cell lung cancer (ES-SCLC).
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-03-01
- Completion
- 2023-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DLL3 CAR-NK cells | Cell therapy | 1e+07 cells | Other |
| Subject | DLL3 CAR-NK cells | Cell therapy | 1e+08 cells | Other |
| Subject | DLL3 CAR-NK cells | Cell therapy | 1e+09 cells | Other |